Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patients

Translational Psychiatry

Volumn 2, Issue , 2012, Pages

  Schwarz, E ^a   Guest, P C ^a   Steiner, J ^b   Bogerts, B ^b   Bahn, S ^a,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Biomarkers; Proteomics; Relapse; Response; Schizophrenia

Indexed keywords

AMPHIREGULIN; APOLIPOPROTEIN C1; BETA 2 MICROGLOBULIN; BETACELLULIN; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; C REACTIVE PROTEIN; CD40 ANTIGEN; CREATINE KINASE MB; FATTY ACID BINDING PROTEIN; FERRITIN; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; GELATINASE B; INSULIN; INTERLEUKIN 6; LEPTIN; MACROPHAGE DERIVED CHEMOKINE; MATRILYSIN; MYOGLOBIN; NEUROLEPTIC AGENT; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OLANZAPINE; OSTEOPONTIN; PROINSULIN; QUETIAPINE; RISPERIDONE; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR LIKE 2 PROTEIN; UNCLASSIFIED DRUG; INTERLEUKIN 16; PROLACTIN;

ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PREDICTIVE VALUE; RELAPSE; SCHIZOPHRENIA; SCORING SYSTEM; TREATMENT OUTCOME; TREATMENT RESPONSE; ADULT; BLOOD; BODY MASS; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; GENETICS; METABOLISM; MIDDLE AGED; PROTEOMICS; PSYCHOLOGICAL RATING SCALE; RECURRENT DISEASE; RISK FACTOR;

ADULT; ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; FEMALE; FERRITINS; HUMANS; INTERLEUKIN-16; MALE; MIDDLE AGED; MYOGLOBIN; PROLACTIN; PROTEOMICS; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; RISK FACTORS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84858055742     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2012.3     Document Type: Article

References (30)

1. Buckley PF, Friedman L, Krowinski AC, Eaton Y, Tronetti M, Miller DD. Clinical and biochemical correlates of 00high-dose00 clozapine therapy for treatment-refractory schizophrenia. Schizophr Res 2001; 49: 225-227. (Pubitemid 32434329)
2. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of secondgeneration antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001; 158: 518-526. (Pubitemid 32289814)
3. Wong EH, Yocca F, Smith MA, Lee CM. Challenges and opportunities for drug discovery in psychiatric disorders: the drug hunters' perspective. Int J Neuropsychopharmacol 2010; 13: 1269-1284.
4. McIlwain ME, Harrison J, Wheeler AJ, Russell BR. Pharmacotherapy for treatmentresistant schizophrenia. Neuropsychiatr Dis Treat 2011; 7: 135-149.
5. Samuels BA, Leonardo ED, Gadient R, Williams A, Zhou J, David DJ et al. Modeling treatment-resistant depression. Neuropharmacology 2011; 61: 408-413.
6. Butterfield LH, Palucka AK, Britten CM, Dhodapkar MV, Hakansson L, Janetzki S et al. Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res 2011; 17: 3064-3076.
7. Hoggatt J. Personalized medicine-trends in molecular diagnostics: exponential growth expected in the next ten years. Mol Diagn Ther 2011; 15: 53-55.
8. Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM et al. Identification of a biological signature for schizophrenia in serum. Mol Psychiatry 2011; e-pub ahead of print.
9. Schwarz E, Izmailov R, Spain M, Barnes A, Mapes JP, Guest PC et al. Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomark Insights 2010; 5: 39-47.
10. Bossuyt PM, Reitsma JB. The STARD initiative. Lancet 2003; 361: 71.
11. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Statist Soc Ser B 1995; 57: 289-300.
12. Barnett AG, van der Pols JC, Dobson AJ. Regression to the mean: what it is and how to deal with it. Int J Epidemiol 2005; 34: 215-220. (Pubitemid 40347398)
13. Breiman L. Random forests. Machine Learning 2001; 45: 5-32. (Pubitemid 32933532)
14. Bland JM, Altman DG. Regression towards the mean. BMJ 1994; 308: 1499. (Pubitemid 24170175)
15. Meyer JM. Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry 2001; 62(Suppl 27): 27-34; discussion 40-21. (Pubitemid 34052254)
16. Yang Y, Wan C, Li H, Zhu H, La Y, Xi Z et al. Altered levels of acute phase proteins in the plasma of patients with schizophrenia. Anal Chem 2006; 78: 3571-3576. (Pubitemid 43848947)
17. Meltzer HY, Fang VS. The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry 1976; 33: 279-286.
18. Guest PC, Schwarz E, Krishnamurthy D, Harris LW, Leweke FM, Rothermundt M et al. Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology 2011; 36: 1092-1096.
19. Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 2009; 119: 4-14.
20. Meltzer HY, Lee MA, Jayathilake K. The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia. Neuropsychopharmacology 2001; 24: 278-290. (Pubitemid 32144813)
21. Czobor P, Volavka J, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J et al. Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol 2002; 22: 244-251. (Pubitemid 34546838)
22. Meltzer HY, Perry E, Jayathilake K. Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr Res 2003; 59: 19-27. (Pubitemid 35291087)
23. Girard J. Is leptin the link between obesity and insulin resistance? Diabetes Metab 1997; 23(Suppl 3): 16-24. (Pubitemid 27428609)
24. Kajikawa Y, Ikeda M, Takemoto S, Tomoda J, Ohmaru N, Kusachi S. Association of circulating levels of leptin and adiponectin with metabolic syndrome and coronary heart disease in patients with various coronary risk factors. Int Heart J 2010; 52: 17-22.
25. Kim BJ, Sohn JW, Park CS, Hahn GH, Koo J, Noh YD et al. Body weight and plasma levels of ghrelin and leptin during treatment with olanzapine. J Korean Med Sci 2008; 23: 685-690.
26. Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 2004; 184: 58-62. (Pubitemid 38085215)
27. Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 2011; 32: 1626-1633.
28. Pannacciulli N, Le DS, Chen K, Reiman EM, Krakoff J. Relationships between plasma leptin concentrations and human brain structure: a voxel-based morphometric study. Neurosci Lett 2007; 412: 248-253. (Pubitemid 46109158)
29. Guest PC, Wang L, Harris LW, Burling K, Levin Y, Ernst A et al. Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naive schizophrenia patients. Mol Psychiatry 2010; 15: 118-119.
30. Arranz B, Rosel P, Ramirez N, Duenas R, Fernandez P, Sanchez JM et al. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry 2004; 65: 1335-1342.